Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Areva Med LLC
DescriptionTrastuzumab combined with lead-212 isotope
Molecular Target
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase I
Standard IndicationSolid tumors
Indication DetailsTreat cancer that has metastasized the abdominal region
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today